Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

BACKGROUND: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. The OPARATIC trial was cond...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Hanna, Catherine, Kurian, Kathreena M, Williams, Karin, Watts, Colin, Jackson, Alan, Carruthers, Ross, Strathdee, Karen, Cruickshank, Garth, Dunn, Laurence, Erridge, Sara, Godfrey, Lisa, Jefferies, Sarah, McBain, Catherine, Sleigh, Rebecca, McCormick, Alex, Pittman, Marc, Halford, Sarah, Chalmers, Anthony J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746945/
https://ncbi.nlm.nih.gov/pubmed/32347934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados